期刊
CLINICAL IMMUNOLOGY
卷 183, 期 -, 页码 213-224出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2017.03.001
关键词
Multiple sclerosis; Microbiome; CNS; Gut-brain axis; Microbial translocation; Intestinal permeability
类别
资金
- Acorda
- Bayer Pharmaceutical
- Biogen Idec
- EMD Serono
- Genzyme
- Novartis
- Questor
- Chugai
- Teva Neuroscience
- NIH NIAID Autoimmune Center of Excellence [UM1-AI110557]
- NIH NINDS [R01-NS080821]
- University of Michigan Neurology Department
Individuals with multiple sclerosis (MS) have a distinct intestinal microbial community (microbiota) and increased low-grade translocation of bacteria from the intestines into the circulation. The observed change of intestinal bacteria in MS patients regulate immune functions involved in MS pathogenesis. These functions include: systemic and central nervous system (CNS) immunity (including peripheral regulatory T cell function), the blood-brain barrier (BBB) permeability and CNS-resident cell activity. This review discusses the MS intestinal microbiota implication on MS systemic- and CNS-immunopathology. We introduce the possible contributions of MS low-grade microbial translocation (LG-MT) to the development of MS, and end on a discussion on microbiota therapies for MS patients. (C) 2017 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据